Stockscreener 앱 받기
27.87
4.07%
1.09
시간 외 거래:
27.80
-0.07
-0.25%
전일 마감가:
$26.78
열려 있는:
$26.63
하루 거래량:
499.61K
Relative Volume:
1.06
시가총액:
$1.08B
수익:
-
순이익/손실:
$-74.31M
주가수익비율:
-11.23
EPS:
-2.4817
순현금흐름:
$-62.86M
1주 성능:
+7.61%
1개월 성능:
+3.07%
6개월 성능:
+65.79%
1년 성능:
+804.87%
1일 변동 폭
$26.47
$28.32
1주일 범위
$25.72
$28.32
52주 변동 폭
$3.00
$28.85
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
27.87 | 1.04B | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-11-17 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
BlackRock (ANRO) discloses 6.0% beneficial ownership in Alto Neuroscience common stock - Stock Titan
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANRO|Alto Neuroscience Inc|Price:26.780|Chg%:-0.080 - TradingKey
Alto Neuroscience Inc (ANRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alto Neuroscience Inc (ANRO) Institutional Confidence - TradingKey
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Alto Neuroscience, Inc. Revenue Breakdown – NYSE:ANRO - TradingView
EcoR1 Capital discloses 5.8% Alto Neuroscience (ANRO) stake in Schedule 13G - Stock Titan
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
Alto Neuroscience Raises Capital to Advance ALTO-207 - TipRanks
Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE - Minichart
Form 424B5 Alto Neuroscience Inc For: 14 July By Investing.com - Investing.com Nigeria
Alto Neuroscience (NYSE: ANRO) sells 3,776,436 shares at $26.48 - Stock Titan
Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting - TradingView
Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale - Stock Titan
Alto Neuroscience Prices $100 Million Stock Offering - Moomoo
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock - AOL.com
Latham Advises on Alto Neuroscience’s US$100 Million Underwritten Registered Direct Offering of Common Stock - Latham & Watkins LLP
Alto Neuroscience prices $100M stock offering at $26.48 - Investing.com UK
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Alto Neuroscience Inc (ANRO) is planning to accelerate and expand the clinical development of its candidate drug Alto-207 by adding a new phase III clinical trial. - Bitget
Alto Neuroscience prices $100M stock offering at $26.48 By Investing.com - Investing.com Australia
Alto Neuroscience (ANRO) Prices $100 Million Stock Offering - GuruFocus
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials - TipRanks
Alto Neuroscience (ANRO) Files Form 8-K Announcing Phase 3 Trial Plans for ALTO-207 in Treatment-Resistant Depression – Minichart - Minichart
Alto Neuroscience (NYSE: ANRO) estimates $244.2M cash and plans added ALTO-207 Phase 3 - Stock Titan
Alto Neuroscience, Inc. Stock 12‑Month Price Target Cut to $34.8, Implies 33% Upside - TradingView
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - AOL.com
Alto Neuroscience (ANRO) Edges Lower as Shares Test Key Support ZoneEquity Put Call - dars.gov.et
ANROAlto Neuroscience Inc Latest SEC Filings - Finviz
Price to sales forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Alto Neuroscience (ANRO) Holds Near Support Amid Slight Dip – Key Levels in FocusIceberg Order - dars.gov.et
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The National Law Review
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider Loss Per Share on Higher R&D SpendingLow Estimate Range - dars.gov.et
Alto Neuroscience, Inc.(NYSE:ANRO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000 Growth Benchmark - marketscreener.com
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol - The National Law Review
Investors SueWallSt as Alto Neuroscience, Inc. Faces Securities Fraud Allegations - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. C - The National Law Review
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):